로그인
보증업체
스포츠중계
스포츠분석
먹튀사이트
지식/노하우
판매의뢰
업체홍보/구인
뉴스
커뮤니티
포토
포인트
보증카지노
보증토토
보증홀덤
스포츠 중계
기타
축구
야구
농구
배구
하키
미식축구
카지노 먹튀
토토 먹튀
먹튀제보
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
제작판매
제작의뢰
게임
구인
구직
총판
제작업체홍보
실시간뉴스
스포츠뉴스
연예뉴스
IT뉴스
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[실시간뉴스]
美, 호주처럼 ‘군사용 핵물질 이전 금지’ 예외 한국에 적용 추진
N
[실시간뉴스]
치매노인 통장-도장 내미니… 제3자도 2분만에 150만원 인출
N
[스포츠뉴스]
충격 또 충격! 안세영, 中 레전드 무너트렸다…세계 1위 125주 누적 달성→리쉐루이 기록 깼다 '역대 4위'
N
[연예뉴스]
라포엠, '팬텀싱어3' 우승 이후 5년…"쉼 없는 질주=사랑의 비결"
N
[스포츠뉴스]
女당구 세계선수권 우승 ‘김가영 수제자’ 서서아, “아시안게임 목표로 최선”
N
커뮤니티
더보기
[자유게시판]
드디어 금요일이군요
[자유게시판]
오늘 다저스 어떻게 생각하시나요
[자유게시판]
하아 댓노
[자유게시판]
식곤증지립니다요
[자유게시판]
벌써 불금이네요
목록
글쓰기
[IT뉴스]Hair Loss Theme Sweeps Korean Market[K-Bio Pulse]
온카뱅크관리자
조회:
18
2025-12-24 08:17:29
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="GINdhdx2rO"> <div contents-hash="b31df665dbc44b115171d9872c491bee34e4a81884e01bdcbb7ca9514ce94cd0" dmcf-pid="HzXSBSIkDs" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on December 17, 2025, at 8:10 AM. </div> </div> <p contents-hash="8c0e997192e0dd93dab3870e6dd2c1f8051d81b3f00cb26c29294f7e5a31e417" dmcf-pid="XqZvbvCEEm" dmcf-ptype="general">[NA Eun-kyung, Edaily Reporter] South Korea’s stock market was swept by a hair loss theme on the 16th, with shares of pharmaceutical companies directly or indirectly linked to hair loss treatments surging to their daily price limits.</p> <p contents-hash="0eaf5584f29838d62b04c0991af88d31dff0b9ec8ef975f6b3eade48c4b4cb1c" dmcf-pid="ZB5TKThDOr" dmcf-ptype="general">Medipost also drew attention after successfully closing a 205 billion won funding round, fueling expectations that its U.S. Phase 3 clinical trial would proceed smoothly. The company’s shares rose by double digits in the over the counter market. Acryl which debuted on the KOSDAQ the same day, climbed 244 percent from its initial public offering price of 19,500 won, marking a strong market debut.</p> <p contents-hash="6c9bb07f01c1defcc982000f9ec99ac953c2b3d3df7b09c824eee2b44ed4e5cb" dmcf-pid="5b1y9ylwIw" dmcf-ptype="general">In contrast, Oscotec retreated sharply after a brief rally despite news of a major deal with Sanofi as tensions with minority shareholders continued to weigh on investor sentiment.</p> <figure class="figure_frm origin_fig" contents-hash="dde8fc181a34c644a7d543921acecd0b6662a52e288fe40b843e11b6aa10c633" dmcf-pid="1KtW2WSrsD" dmcf-ptype="figure"> <p class="link_figure"><img alt="Withuspharm’s share price began rebounding at around 2:30 p.m. on the 16th and closed the session at its daily upper limit. (Source: Toss Securities)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/24/Edaily/20251224081304812tgbm.jpg" data-org-width="644" dmcf-mid="WuLxsx8BIC" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/24/Edaily/20251224081304812tgbm.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Withuspharm’s share price began rebounding at around 2:30 p.m. on the 16th and closed the session at its daily upper limit. (Source: Toss Securities) </figcaption> </figure> <p contents-hash="1445992dab4453fc4f3d7f87741645528d64784cd2bbadaaf1894e721aeb5b45" dmcf-pid="t9FYVYvmEE" dmcf-ptype="general"><strong>“Hair Loss Is a Matter of Survival”; Related Shares Surge</strong></p> <p contents-hash="ae0099a769db43f07a66a3e9a53532ee8620c2684c85b18942323527204c6acd" dmcf-pid="F23GfGTsOk" dmcf-ptype="general">The rally in hair loss related stocks was sparked by remarks from President Lee Jae-myung. During a Ministry of Health and Welfare briefing in the afternoon, Lee described hair loss as “a matter of survival” and urged Health Minister Jung Eun kyung to review the possibility of including hair loss treatments in national health insurance coverage, noting that coverage could help lower drug prices.</p> <p contents-hash="1254a3f4b8ba7a5c3ba9444737efebabcd33a4403373cc209197e2dd35e4c6b0" dmcf-pid="3V0H4HyOsc" dmcf-ptype="general">Following media reports at around 2:20 p.m., shares of hair loss drug makers began to soar. Among the biggest gainers were Withuspharm, up 29.8 percent, JW shinyak up 26.1 percent and Hyundai Pharm, up 11.1 percent.</p> <p contents-hash="7536557cb8fc9296eb6ce0721931870c2999eee5916c151664012b2bfab11ddc" dmcf-pid="0TDgWgiPrA" dmcf-ptype="general">JW shinyak and Hyundai Pharm were seen as direct beneficiaries as both companies already market multiple hair loss treatments. In South Korea, only three active ingredients are approved for hair loss drugs finasteride, dutasteride and minoxidil.</p> <p contents-hash="5ec00cb892eebf1bcb58f7124159fbe8dac17816c241a4061064b7b419b89920" dmcf-pid="pywaYanQOj" dmcf-ptype="general">JW shinyak sells Dutamoa which contains dutasteride Monad, based on finasteride; and Mydil, which uses minoxidil. Last year, the company also began distributing and selling Ducray Neoptide Expert a hair care cosmetic product under an exclusive domestic supply agreement with France’s Pierre Fabre.</p> <p contents-hash="8cc97d92166ae7f70b0f193f0c9394e90245ce47ce63838ccf52220b106b1c60" dmcf-pid="UWrNGNLxrN" dmcf-ptype="general">Hyundai Pharm markets Damodart a dutasteride-based product Minofesia which contains finasteride and Mynoxil a minoxidil formulation. The company has a strong presence as a pioneer in the topical minoxidil market. </p> <p contents-hash="10aa98b796c8b887c1a7e7229bcf51a5488312af1866f5abacf49d5840278cbf" dmcf-pid="uYmjHjoMra" dmcf-ptype="general">Withuspharm’s rally was largely attributed to expectations surrounding IVL3001, though analysts note that the company is still some distance away from monetization compared with JW New Drug and Hyundai Pharm which already generate revenue from marketed products.</p> <p contents-hash="51f28a9f5816e71a3dc37c16a07cf149b6d0f62bd92cad0061ee76ba8df7889e" dmcf-pid="7GsAXAgRsg" dmcf-ptype="general">IVL3001 is a finasteride-based hair loss treatment being co developed by Inventage Lab and Daewoong Pharmaceutical. The product is designed as a once monthly injectable formulation. Withers Pharmaceutical is a contract manufacturing partner of Inventage Lab and is set to receive royalties in the double-digit percentage range on shipments once the product is launched.</p> <p contents-hash="5622fab363a9057ae9ad59e9d89f459501f062f38e64a4ca8d1345e8dafe1adc" dmcf-pid="zHOcZcaemo" dmcf-ptype="general">Inventage Lab submitted an investigational new drug application for a Phase 2 trial of IVL3001 to Australia’s Therapeutic Goods Administration on March 10.</p> <p contents-hash="1832f8e4e2c097a67934a627907cfb035511643779417f339c88bb944e2077ab" dmcf-pid="qXIk5kNdIL" dmcf-ptype="general">The domestic market for hair loss treatments was estimated at 115 billion won in 2021. Including health supplements and food products, the broader hair loss related market in South Korea is estimated at 4 trillion to 5 trillion won annually.</p> <p contents-hash="d00e8ecbc5925a067fffa7139bb68df109d95d797940f8aab15d13d703458b9f" dmcf-pid="BZCE1EjJDn" dmcf-ptype="general"><strong>Medipost Shares Rise on Funding Success</strong></p> <figure class="figure_frm origin_fig" contents-hash="b32004207d4954334933ee9d8ee02d273e3d02dff06d3309ff9ecc9c985166f5" dmcf-pid="bjMVcVb0si" dmcf-ptype="figure"> <p class="link_figure"><img alt="Medipost’s 'Cartistem' for knee osteoarthritis (Source: Medipost)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/24/Edaily/20251224081306264nlkw.jpg" data-org-width="745" dmcf-mid="Ys8BgBu5EI" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/24/Edaily/20251224081306264nlkw.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Medipost’s 'Cartistem' for knee osteoarthritis (Source: Medipost) </figcaption> </figure> <p contents-hash="243693537ce1c1292190aa739c295cc12bb90d5e23d30cba0b02396076491f9c" dmcf-pid="KARfkfKpmJ" dmcf-ptype="general">Medipost’s shares climbed 13.8 percent in the Nextrade after-market, defying the usual negative reaction to news of convertible bond issuance.</p> <p contents-hash="4892d3b225d76f17872b95110215a7ba501a48af292675c992faf07e29701e5d" dmcf-pid="9ce4E49Uwd" dmcf-ptype="general">The rebound was attributed to strong participation from major shareholders Skylake Equity Partners and Crescendo Equity Partners, as well as new domestic investors in the bond offering. Investor optimism was also supported by expectations that global commercialization of the company’s flagship product, Cartistem, is nearing.</p> <p contents-hash="70481bfeb7ca6b04756997455559e5c3f2ef29bee064e6d04460d78d6f0c0f71" dmcf-pid="2kd8D82uwe" dmcf-ptype="general">Medipost recently completed a Phase 3 clinical trial of Cartistem for knee osteoarthritis in Japan and is preparing to launch a Phase 3 trial in the United States next year. The 205 billion won funding round disclosed this week is intended to finance the U.S. trial. While earlier market estimates had put the fundraising size at around 250 billion won, the final amount came in slightly lower.</p> <p contents-hash="00c84fdb9944773b71aff2df084f142044fc05a4854e8323e962b8c34cb65424" dmcf-pid="VEJ6w6V7ER" dmcf-ptype="general">The company completed dosing in 130 patients for the Japanese Phase 3 trial in November last year and is currently conducting follow up observations. The final patient completed a one year follow up last month. Medipost plans to compile the data and disclose the clinical study report for the Japanese trial in the first half of next year.</p> <p contents-hash="abdcaf2abbd5d55823e330afddfd8836e231a17deb742981f357a1b4fe08ffc8" dmcf-pid="fDiPrPfzwM" dmcf-ptype="general">A company official said Medipost aims to apply for marketing approval with Japan’s Pharmaceuticals and Medical Devices Agency in the second half of next year and begin dosing the first patient in the U.S. Phase 3 trial in the first half.</p> <p contents-hash="37abf17a64b655d658efdd436451997b559803af71c258a0e2b3be45afe18991" dmcf-pid="4wnQmQ4qmx" dmcf-ptype="general">Cartistem, approved by South Korea’s Ministry of Food and Drug Safety in 2012, is the country’s first stem cell therapy to be used in clinical practice for more than a decade. Last year, Cartistem generated 20.2 billion won in sales accounting for 27 percent of Medipost’s total revenue. </p> <p contents-hash="502919a27d2083f538a9ac0296885def53c00304b813d6076560de20b83daf3f" dmcf-pid="8rLxsx8BEQ" dmcf-ptype="general">The company is currently conducting a real world evidence study involving more than 500 domestic patients to quantitatively demonstrate the long-term outcomes of Cartistem treatment.</p> <p contents-hash="970f978c6830fb1d4f90b1569900378609cd7d12e163b59156a4e1c80f621d4f" dmcf-pid="6ARfkfKpIP" dmcf-ptype="general"><strong>Oscotec Falls Despite 1.5 Trillion Won Deal</strong></p> <p contents-hash="a4148334fe4beb8333babeee8238d2769a3c681247d55a5f37e6c7ec810db316" dmcf-pid="Pce4E49Uw6" dmcf-ptype="general">Oscotec ended the day with a double digit decline despite announcing a major licensing deal with a global pharmaceutical company.</p> <p contents-hash="a8f2d8396b361ccb56b3efce548f9b938a76ee79f78f8781905b7f100a91c47f" dmcf-pid="Qkd8D82uO8" dmcf-ptype="general">The company’s shares closed down 11.2 percent at 54,400 won. Ahead of the market open, Oscotec disclosed a major agreement with Sanofi sending the stock up 29.8 percent to 79,600 won in Nextrade’s pre-market session but the rally quickly faded. Ongoing disputes with minority shareholders were seen as a key drag on the stock.</p> <p contents-hash="7f984c56e8b8a9b82dca485b3a665a8199fa620fe02f92a40ad7678c7e8ff304" dmcf-pid="xEJ6w6V7s4" dmcf-ptype="general">Oscotec licensed out ADEL-Y01, an Alzheimer’s disease drug candidate co-developed with unlisted biotech firm ADEL, to Sanofi. The deal is worth up to $1.04 billion, or about 1.53 trillion won, including an upfront payment of $80 million, or roughly 118 billion won. The upfront portion accounts for 7.7 percent of the total contract value, a relatively high ratio compared with the typical 3 to 5 percent seen in licensing deals between Korean companies and global pharmaceutical firms.</p> <p contents-hash="dfa64cf0819f5ec4e8b0568b1ff78dd7a7b4345c341d6527a2a4f8903588f32a" dmcf-pid="yzXSBSIkmf" dmcf-ptype="general">ADEL-Y01 was developed by ADEL, founded by Professor Yoon Seung-yong of Asan Medical Center in Seoul. Oscotec entered a joint research and development agreement with ADEL in October 2020 and has since overseen manufacturing as well as preclinical and clinical development.</p> <p contents-hash="a961e246dcbb7356646e625bd301eee73c6a03c656d0329e8742a4a95a95934b" dmcf-pid="WqZvbvCEIV" dmcf-ptype="general">PharmEdaily reported that profits from ADEL-Y01 will be split 53 percent to ADEL and 47 percent to Oscotec under the agreement. As a result, Oscotec will receive about 55.3 billion won from the upfront payment alone. The company posted revenue of 34 billion won last year, making the deal a significant boost after recent attempts to raise external funding fell through.</p> <p contents-hash="6f030f34f54ec4e951760bacea54651fe1b47a5c91dca6cc942dc45835b0b236" dmcf-pid="YB5TKThDw2" dmcf-ptype="general">Oscotec Chief Executive Officer Yoon Tae-young said the licensing agreement transfers full development rights for ADEL-Y01 to Sanofi, adding that no additional research and development costs will be incurred by Oscotec or ADEL going forward.</p> <p contents-hash="b2f47624bb2e0dc1d5433ad280d7c94c53a4f0f3edbd07734881695bef2d9653" dmcf-pid="Gb1y9ylwr9" dmcf-ptype="general">나은경 (eeee@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기